Can Redhill Biopharma Ltd. (NASDAQ:RDHL) Beat $-0.58 Per Share?

Wall Street analysts on the sell-side are anticipating that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report earnings of $-0.64 per share when the company issues their quarterly report today.  This is the consensus earnings per share number according to data from Zack’s Research. 

Most recently Redhill Biopharma Ltd. (NASDAQ:RDHL) reported a surprise factor of 21.88%. The actual number was $0.14 away from the Zacks consensus just prior to the actual release. A significant surprise factor can lead to stock swings in the price in the hours and days following the earnings report.

Projected Stock Movement
Research analysts covering shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) are anticipating on a consensus basis that the stock will reach $28 within the next 52 weeks. Of the analysts providing short term targets, the most bullish analyst has a $33 target on the stock. On the other end, the most conservative has a short term target of $25. This is based on the 3 analysts taken into consideration by Zacks. The consensus price target was last revised on 2017-05-04.

Zacks also provides a simplified scale for analyst recommendations. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. Redhill Biopharma Ltd. (NASDAQ:RDHL) currently has an ABR of 1 heading into today’s announcement. This number is also based on the 3 sell-side firms polled by Zacks.

It may be difficult for many investors to decide the right time to buy or sell a stock. Veteran investors may seem like they have it all figured out, and amateurs may feel like they are swimming upstream. Seasoned traders may have spent many years monitoring market ebbs and flows. Knowing when to take profits or cut losses can be a tough skill to achieve. It might be hard letting go of a well researched stock that hasn’t been performing well. Being able to exit a trade that has gone south can be a portfolio saver in the long run.

This article is informational purposes only and should not be considered a recommendation to buy or sell Redhill Biopharma Ltd.. 

Leave a Comment